MedTrace Logo

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

NCT05667246 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-10-01

No results posted yet for this study

Summary

The investigators hypothesize that there would be significant changes in blood pressure or heart rate in patients consuming caffeine while taking terbinafine.

Conditions

  • Terbinafine Adverse Reaction

Interventions

OTHER

Caffeinated Coffee

Subjects would be randomized to a group "Caffeinated" and subjects will be 95 mg of caffeine in caffeinated coffee.

OTHER

Decaffeinated Coffee

Subjects would be randomized to a group "Decaffeinated" and subjects will be no caffeine in decaffeinated coffee.

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Shari Lipner, MD, PhD · Weill Medical College of Cornell University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-25
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667246 on ClinicalTrials.gov